Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Sells $48,414.22 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Zachary Roberts sold 27,199 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the sale, the executive vice president now owns 488,054 shares of the company’s stock, valued at $868,736.12. The trade was a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Allogene Therapeutics Stock Down 2.1 %

Allogene Therapeutics stock traded down $0.04 during trading hours on Thursday, hitting $1.88. The stock had a trading volume of 1,389,630 shares, compared to its average volume of 2,946,952. The company has a 50-day moving average of $2.14 and a two-hundred day moving average of $2.52. Allogene Therapeutics, Inc. has a fifty-two week low of $1.78 and a fifty-two week high of $5.78. The company has a market cap of $394.18 million, a PE ratio of -1.21 and a beta of 0.86.

Analyst Ratings Changes

A number of research analysts have weighed in on ALLO shares. William Blair reissued an “outperform” rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a research note on Friday, November 8th. Finally, Piper Sandler dropped their price target on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.73.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Private Advisor Group LLC acquired a new stake in Allogene Therapeutics during the third quarter worth $34,000. Federated Hermes Inc. acquired a new stake in shares of Allogene Therapeutics during the 2nd quarter valued at about $29,000. Algert Global LLC bought a new stake in Allogene Therapeutics in the second quarter valued at about $35,000. MML Investors Services LLC bought a new position in Allogene Therapeutics during the third quarter worth about $56,000. Finally, EP Wealth Advisors LLC lifted its stake in Allogene Therapeutics by 125.6% during the third quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock worth $69,000 after purchasing an additional 13,625 shares during the period. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).